JP4970946B2 - モルホリン化合物 - Google Patents

モルホリン化合物 Download PDF

Info

Publication number
JP4970946B2
JP4970946B2 JP2006535186A JP2006535186A JP4970946B2 JP 4970946 B2 JP4970946 B2 JP 4970946B2 JP 2006535186 A JP2006535186 A JP 2006535186A JP 2006535186 A JP2006535186 A JP 2006535186A JP 4970946 B2 JP4970946 B2 JP 4970946B2
Authority
JP
Japan
Prior art keywords
substituent
methyl
morpholin
ylthio
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006535186A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2006028284A1 (ja
Inventor
善仁 田中
秀造 武田
秀光 東
衛 松浦
不二夫 小林
真以子 濱田
実 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to JP2006535186A priority Critical patent/JP4970946B2/ja
Publication of JPWO2006028284A1 publication Critical patent/JPWO2006028284A1/ja
Application granted granted Critical
Publication of JP4970946B2 publication Critical patent/JP4970946B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2006535186A 2004-09-08 2005-09-08 モルホリン化合物 Expired - Fee Related JP4970946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006535186A JP4970946B2 (ja) 2004-09-08 2005-09-08 モルホリン化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004261655 2004-09-08
JP2004261655 2004-09-08
JP2006535186A JP4970946B2 (ja) 2004-09-08 2005-09-08 モルホリン化合物
PCT/JP2005/017002 WO2006028284A1 (ja) 2004-09-08 2005-09-08 モルホリン化合物

Publications (2)

Publication Number Publication Date
JPWO2006028284A1 JPWO2006028284A1 (ja) 2008-05-08
JP4970946B2 true JP4970946B2 (ja) 2012-07-11

Family

ID=36036551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006535186A Expired - Fee Related JP4970946B2 (ja) 2004-09-08 2005-09-08 モルホリン化合物

Country Status (13)

Country Link
US (1) US7935700B2 (US06903085-20050607-C00010.png)
EP (1) EP1801108B9 (US06903085-20050607-C00010.png)
JP (1) JP4970946B2 (US06903085-20050607-C00010.png)
KR (1) KR101011848B1 (US06903085-20050607-C00010.png)
CN (1) CN101014580B (US06903085-20050607-C00010.png)
CA (1) CA2579207C (US06903085-20050607-C00010.png)
DK (1) DK1801108T3 (US06903085-20050607-C00010.png)
ES (1) ES2396419T3 (US06903085-20050607-C00010.png)
IN (1) IN2014CN03493A (US06903085-20050607-C00010.png)
PL (1) PL1801108T3 (US06903085-20050607-C00010.png)
PT (1) PT1801108E (US06903085-20050607-C00010.png)
TW (1) TW200619212A (US06903085-20050607-C00010.png)
WO (1) WO2006028284A1 (US06903085-20050607-C00010.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846401B1 (en) * 2005-02-04 2008-06-18 CTG Pharma S.r.l. New 4-aminoquinoline derivatives as antimalarials
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
EP1971583B1 (en) * 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US8030303B2 (en) 2006-07-11 2011-10-04 Mitsubishi Tanabe Pharma Corporation Salt of morpholine compound
US20080146624A1 (en) * 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
JP5319532B2 (ja) * 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058178A1 (en) * 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008123582A1 (ja) 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物
LT2824100T (lt) 2008-07-08 2018-05-10 Incyte Holdings Corporation 1,2,5-oksadiazolai, kaip indolamino 2,3-dioksigenazės inhibitoriai
TWI679978B (zh) * 2013-07-24 2019-12-21 日商田邊三菱製藥股份有限公司 眼科疾病治療劑
AR098343A1 (es) 2013-11-08 2016-05-26 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
WO2020203822A1 (ja) * 2019-03-29 2020-10-08 千寿製薬株式会社 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
US20220280487A1 (en) * 2019-08-26 2022-09-08 Stichting Vumc Inhibition of mycobacterial type vii secretion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264467A (ja) * 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
JPH03148276A (ja) * 1989-11-01 1991-06-25 Yoshitomi Pharmaceut Ind Ltd 光学活性なピリドンカルボン酸化合物
WO2000053600A1 (fr) * 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Derives piperidiniques
WO2003082294A1 (en) * 2002-03-28 2003-10-09 Glaxo Group Limited Morpholine derivatives with a substituted acetamide group in the 2-position for use as ccr-3 antagonists for the treatment of inflammatory diseases
WO2004004731A1 (en) * 2002-07-02 2004-01-15 F. Hoffmann-La Roche Ag 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix
JP2004509952A (ja) * 2000-09-29 2004-04-02 グラクソ グループ リミテッド 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284687B6 (cs) * 1986-04-30 1999-02-17 Dainippon Pharmaceutical Co., Ltd. Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU3633997A (en) 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
EP1076557A1 (en) 1998-04-27 2001-02-21 Smithkline Beecham Corporation Ccr-3 receptor antagonists
CA2329821A1 (en) 1998-04-27 1999-11-04 Dashyant Dhanak Ccr-3 receptor antagonists
KR20010081034A (ko) 1998-11-20 2001-08-25 프리돌린 클라우스너, 롤란드 비. 보레르 피페리딘 씨씨알-3 수용체 길항제
WO2000034278A1 (fr) 1998-12-04 2000-06-15 Toray Industries, Inc. Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif
CA2361366A1 (en) 1999-03-26 2000-10-05 Nicholas Kindon Novel compounds
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
WO2002018335A1 (fr) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amine cyclique
EP1586567A1 (en) 2000-09-29 2005-10-19 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
KR20040015191A (ko) 2001-04-27 2004-02-18 미쯔비시 웰 파마 가부시키가이샤 신규 벤질피페리딘 화합물
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207445D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207439D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0208158D0 (en) 2002-03-28 2002-05-22 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0212355D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264467A (ja) * 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
JPH03148276A (ja) * 1989-11-01 1991-06-25 Yoshitomi Pharmaceut Ind Ltd 光学活性なピリドンカルボン酸化合物
WO2000053600A1 (fr) * 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Derives piperidiniques
JP2004509952A (ja) * 2000-09-29 2004-04-02 グラクソ グループ リミテッド 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体
WO2003082294A1 (en) * 2002-03-28 2003-10-09 Glaxo Group Limited Morpholine derivatives with a substituted acetamide group in the 2-position for use as ccr-3 antagonists for the treatment of inflammatory diseases
WO2004004731A1 (en) * 2002-07-02 2004-01-15 F. Hoffmann-La Roche Ag 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix

Also Published As

Publication number Publication date
JPWO2006028284A1 (ja) 2008-05-08
CN101014580B (zh) 2011-05-04
DK1801108T3 (da) 2013-02-18
CA2579207A1 (en) 2006-03-16
WO2006028284A1 (ja) 2006-03-16
CN101014580A (zh) 2007-08-08
TWI367209B (US06903085-20050607-C00010.png) 2012-07-01
EP1801108A4 (en) 2010-10-13
IN2014CN03493A (US06903085-20050607-C00010.png) 2015-07-03
TW200619212A (en) 2006-06-16
EP1801108A1 (en) 2007-06-27
KR101011848B1 (ko) 2011-02-01
US20070265257A1 (en) 2007-11-15
KR20070099528A (ko) 2007-10-09
EP1801108B9 (en) 2013-11-20
ES2396419T3 (es) 2013-02-21
US7935700B2 (en) 2011-05-03
PL1801108T3 (pl) 2013-04-30
PT1801108E (pt) 2012-12-03
CA2579207C (en) 2011-10-18
EP1801108B1 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
JP4970946B2 (ja) モルホリン化合物
US10392375B2 (en) Heteroaryl compounds as IRAK inhibitors and uses thereof
JP4261914B2 (ja) 新規ベンジルピペリジン化合物
US20030069169A1 (en) Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
JP7157764B2 (ja) 新規なピペリジン-2,6-ジオン誘導体及びその用途
WO2004037817A1 (ja) N−オキシド化合物
US20070010537A1 (en) Fused pyramidine derivative and use thereof
BR122017002951A2 (pt) amidas heterocíclicas como inibidores de quinases
CA2694284A1 (en) Heterocyclic compounds useful as raf kinase inhibitors
EP2083816A2 (en) Heterocyclic amide compounds useful as kinase inhibitors
CA2693182A1 (en) Pyrimidine compounds, methods of synthesis thereof, and use thereof in the treatment of raf kinase-mediated disorders
CA2745121A1 (en) Morpholinone compounds as factor ixa inhibitors
BG65683B1 (bg) Заместени оксазолидинони и тяхното приложение в областта на кръвосъсирването
WO2005019188A1 (ja) 縮合ピリミジン誘導体およびその用途
MX2014009281A (es) Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina.
WO2005111037A1 (en) Beta-carbolines useful for treating inflammatory disease
JP2021522253A (ja) 化合物及びその使用
JP2005097276A (ja) 縮合ピリミジン誘導体およびその用途
WO2023230609A1 (en) Heterocyclic pad4 inhibitors
ES2366114T3 (es) Derivados de 3,4-dihalobencilpiperidina y su uso médico.
WO2023230612A1 (en) Heterocyclic pad4 inhibitors
KR20230155834A (ko) Ido/tdo 이중 저해용 화합물 및 이를 포함하는 약학적 조성물
AU2002245601A1 (en) Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120403

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150413

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4970946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees